Reported 2 days ago
Summit Therapeutics Inc. is reportedly in talks with AstraZeneca regarding a potential $15 billion licensing agreement for the lung cancer drug ivonescimab. While negotiations are ongoing, the deal could include a substantial upfront payment and future milestones, although it may not be finalized, as Summit might opt for a different partnership. Summit acquired rights to ivonescimab through a $5 billion deal with Akeso in December 2022.
Source: YAHOO